Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Authors||E. Lew, C. Walsh, E. Martin, A. Albert, G.G. Li, Y. Yokoyama|
|Title||Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor|
|Journal||European Journal of Cancer|
|Abstract Text||European Journal of Cancer, Vol 69, Supplement 1, December 2016, Page S31|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RXDX-106||CEP-40783||AXL Inhibitor 27 MERTK Inhibitor 9 MET Inhibitor 51 TYRO3 Inhibitor 8||RXDX-106 is a small molecule inhibitor of TAM family kinases (Axl, Mertk, and Tyro3) and Met that promotes anti-tumor immune response, resulting in tumor growth inhibition (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31, PMID: 30501104).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast carcinoma||not applicable||RXDX-106 + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, RXDX-106 in combination with an unspecified anti-PD-1 antibody resulted in near complete regression in orthotopic animal models of breast carcinoma (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31).||detail...|
|Unknown unknown||breast carcinoma||not applicable||RXDX-106||Preclinical||Actionable||In a preclinical study, RXDX-106 inhibited tumor growth in orthotopic animal models of breast carcinoma (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31).||detail...|